The effects of omega-3 polyunsaturated fatty acids (PUFAs) on cerebral vessels have not been clarified until now. Thus we investigated the efficacy of omega-3 PUFAs supplementation on cerebral blood flow velocity and vascular resistance via transcranial doppler (TCD). Methods: Consecutive twenty patients (13 male and 7 female) with at least 1 cerebrovascular risk factor or a known cerebrovascular disease were enrolled. Patients were treated with omega-3 PUFAs (1 g, two times per day) for 12 weeks. Cerebral blood flow velocity, resistance index, and pulsatile index were checked before and after 12 weeks of treatment using TCD. Results: The change of resistance index in right MCA (from 0.58 ± 0.07 to 0.55 ± 0.07, p = 0.042) and left PCA (from 0.56 ± 0.07 to 0.53 ± 0.06, p = 0.037) showed significant improvement after 12 weeks of omega-3 PUFAs treatment. The changes in other vessels, however, failed to show any significant changes compared to the baseline. Conclusions: Omega-3 PUFAs treatment showed feasible efficacies for cerebral vascular resistances in this open label trial. To confirm these results, larger samples of patients and longer period of follow-up is warranted. (Korean J Clin Neurophysiol 2015;17:68-72) 
Introduction
Omega-3 polyunsaturated fatty acids (PUFAs) supplements reduced mortality in secondary prevention studies.
1,2 Dietary supplementation with omega-3 PUFAs (1 g daily) in patients who had a history of myocardial infarction showed significant benefit in the risk of death and cardiovascular death. 1 Moreover, the myocardial infarction patients who were advised to eat fatty fish for polyunsaturated fat had a significant reduction in all cause mortality compared with those not so advised. 6, 7 In this study, we planned to investigate the effect of omega-3 PUFAs on cerebral blood flow and vascular resistance in patients with cerebrovascular risk factors.
Materials and Methods

Subjects
Twenty patients with having cerebrovascular risk factors were recruited in a general hospital. The inclusion criteria were age older than 40 years and having at least 1 cerebrovascular risk factor or a known cerebrovascular disease, such as stroke history, hypertension, diabetes, dyslipidemia, and heart disease. 
Measurement of cerebral blood flow and vascular resistance
Cerebral blood flow velocity and vascular resistance were measured using TCD (Nicolet Pioneer TC8080). The anterior We compared the results of cerebral blood flow velocity and vascular resistance (PRI and GPI) between baseline and 12 weeks after treatment using SPSS Ver 11.5 for Windows (SPSS Inc., Chicago, USA). The T-test for paired samples was used for the analysis and the two-tailed level of significance for all tests was set at 0.05.
Results
The mean age of the 20 patients (13 male) was 64.35 ± 10.34 years. The baseline characteristics are shown in Table 1 .
There was no change in blood pressure during 12 weeks, so In addition, omega-3 PUFAs did not have any effect on cerebral blood flow velocity in bilateral ACA, MCA, and PCA (Table 2) .
Discussion
We evaluated the efficacy of omega-3 PUFAs on cerebral blood flow velocity and vascular resistance and found that omega-3 PUFAs treatment improved the cerebral arterial resistance index of right MCA and left PCA in patients with cerebrovascular risk factors.
Though the cerebral vascular resistance index or pulsatile index could be affected by various factors, such as calcification, liver cirrhosis, and so on, it could be assessed as a surrogate marker of cerebrovascular atherosclerosis. [11] [12] [13] In line with these studies, the resistance index has been regarded as a noninvasive evaluation method of the endothelial function. 14 The exact mechanism of omega-3 fatty acids on endothelial function is not fully understood, but several theories have been proposed. 7 Reduced production of the vasoconstrictor thromboxane A2 and increased synthesis of the vasodilator nitric oxide are thought to be one of the main action mechanisms in improving endothelial function. 7, 15, 16 Suggested hypothesis included affecting inflammation via modifying eicosanoid biosynthesis. 17 It also could be precursor to resolvins, protectins, and other inflammation resolving mediators having anti-inflammtory properties. 18 It has been proposed for the arterial stiffness, the incorporation of omega-3 PUFAs into atherosclerotic plaques can enhance stability by reducing macrophage infiltration and stabilizing plaque morphology.
rial stiffness was shown in patients with peripheral arterial disease. 4 The dietary intake of omega-3 PUFAs from fish also failed to show any efficacy on endothelial function and arterial stiffness in healthy non-smoking persons. 5 In addition, supplements long chain ω-3 fatty acids failed to show association with risk of cerebrovascular disease. 3 So they suggested that not a single nutrients but a wide range of nutrients abundant in fish mediated the beneficial effect of fish intake on cerebrovascular risk. 3 Contrary to this, Kim et al. investigated the plasma phospholipid fatty acid composition in ischemic stroke. 20 Low level of plasma DHA, reflecting dietary intake deficiency, is suggested to elevate the risk of ICAS (Intracerebral arterial stenosis). 20 Treatment with 2 g/day omega-3 PUFAs showed a significant improvement in FMD (flow-mediated dilation) as endothelial function and PWV (pulse wave velocity) as aortic stiffness in patients with metabolic syndrome. 7 The discrepancies among the result of previous studies could be due to differences in the inclusion criteria, omega-3 PUFAs doses, and used tools to estimate endothelial function. 6 We suggested anti-inflammatory and plaque stabilization effects. 6, 7 Though this is preliminary, the small sample number, relatively short duration, and no control group were the main limitations in our study. In addition, specific biological markers are needed to elucidate the action mechanism of omega-3
PUFAs on endothelium. These short comings warrant the further large-scale, long-term, detailed study.
